.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XA03_Telavancin.Telavancin .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XA03_Telavancin.Telavancin| name: | Telavancin |
| ATC code: | J01XA03 | route: | intravenous |
| n-compartments | 2 |
Telavancin is a lipoglycopeptide antibiotic used for the treatment of complicated skin and skin structure infections (cSSSI) and hospital-acquired and ventilator-associated bacterial pneumonia caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved for intravenous use in adults.
Pharmacokinetic parameters observed in adult healthy volunteers and infected patients from clinical studies. The data provided generally reflect administration of a single 10 mg/kg intravenous infusion over 60 minutes.
Ullah, S, et al., & Taubert, M (2019). A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure. Naunyn-Schmiedeberg's archives of pharmacology 392(9) 1097–1106. DOI:10.1007/s00210-019-01647-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/31062064
Lodise, TP, et al., & Drusano, GL (2008). Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrobial agents and chemotherapy 52(7) 2300–2304. DOI:10.1128/AAC.01110-07 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18426898